Launch pricing ends soon — save 20% on every template with code CLINIC20
$97.00
A complete, attorney-reviewed informed consent form for semaglutide (GLP-1) weight-loss treatment. It covers the compounded-vs-brand disclosure, risks, side effects and monitoring requirements every weight-loss program needs to document.
Weight-loss clinics, med spas and telehealth programs prescribing semaglutide. Built for clinics that need to document informed consent for compounded or brand GLP-1 therapy and the associated monitoring.
Generic weight-loss consents rarely address compounded semaglutide or the specific contraindications and monitoring GLP-1 therapy requires — the parts regulators and plaintiffs focus on.
Download the editable Word file, add your clinic details, pair it with the GLP-1 screening form, and use it for every semaglutide patient. PDF included.
The treatment and mechanism, compounded-vs-brand disclosure, risks and side effects, dosing and monitoring, contraindications, and dated signatures — all included here.
Yes. The compounded-vs-brand disclosure is built in.
The GLP-1 screening & eligibility form — use it before this consent to document eligibility.
The form is suitable for in-person and telehealth programs; a telehealth acknowledgment can be added.
